HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Fosphenytoin
XWLUWCNOOVRFPX-UHFFFAOYSA-N · 2,4-Imidazolidinedione, 5,5-diphenyl-3-[(phosphonooxy)methyl]-

Identifikatoren & physikalische Daten
| CAS No. | 93390-81-9 |
|---|---|
| Summenformel | C16H15N2O6P |
| Durchschnittliche Molmasse | 362,27 g/mol |
| Monoisotopische Masse | 362,06677283 g/mol |
| SMILES | O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O |
| InChIKey | XWLUWCNOOVRFPX-UHFFFAOYSA-N |
| PubChem CID | 56339 |
| ChEMBL | CHEMBL1201336 |
| ChEBI | CHEBI:5165 |
| DTXSID | DTXSID9044299 |
Chemische & physikalische Eigenschaften
| XLogP | 0,6 |
|---|---|
| Polarare Oberfläche (TPSA) | 116 |
| H-Brücken-Donoren | 3 |
| H-Brücken-Akzeptoren | 6 |
| Frei drehbare Bindungen | 5 |
| Schwere Atome | 25 |
| Formalladung | 0 |
| Komplexität | 547 |
| Arzneimittel | PharmaceuticalsPharmaceuticals -> AntiepilepticsPharmaceuticals -> Listed in ZINC15 |
| Color/Form | White crystals from acetone |
| Löslichkeit | Mol wt: 406.24. White crystals as the dihydrate from water-ethanol-acetone, mp 220 °C (softens). pH of a saturated aqueous solution: approx 9. Solubility at 25 °C (mg/mL): 142 in water /Disodium salt/1.45e-01 g/L |
| Human Drugs | Breast FeedingLactationMilk, HumanAnticonvulsants |
| Schmelzpunkt | 173-176.5 °C173-176.5° |
| Physical Description | Solid |
| Dichte | 1.495±0.06 g/cm3(Predicted) |
| pKa (Säurekonstante) | 1.74±0.10(Predicted) |
Sicherheit & Vorschriften
| FDA-Anforderungen | The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl fosphenytoin approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. |
|---|---|
| Entsorgungsverfahren | SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices. |
| Treatment | Treatment is nonspecific since there is no known antidote to Fosphenytoin overdosage. The adequacy of the respiratory and circulatory systems should be carefully observed, and appropriate supportive measures employed. Hemodialysis can be considered since phenytoin is not completely bound to plasma proteins. Total exchange transfusion has been used in the treatment of severe intoxication in children. (L1712) |
| Wechselwirkungen | Risk of hepatotoxicity from a single toxic dose or prolonged use of acetaminophen may be increased and therapeutic efficacy may be decreased in patients regularly taking other hepatic enzyme-inducing agents such as phenytoin. /Hydantoin anticonvulsants/Concurrent use of alcohol or CNS depression-producing medications with hydantoin anticonvulsants may enhance CNS depression. Chronic use of alcohol may decrease serum concentrations and effectiveness of hydantoinsconcurrent use of hydantoin anticonvulsants with acute alcohol intake may increase serum hydantoin concentrations. /Hydantoin anticonvulsants/Concurrent use of amiodarone with phenytoin and possibly with other hydantoin anticonvulsants may increase plasma concentrations of the hydantoin, resulting in increased effects and/or toxicity. /Hydantoin anticonvulsants/Concurrent use with coumarin- or indandione-derivative anticoagulants, chloramphenicol, cimetidine, disulfiram, influenza virus vaccine, isoniazid, methylphenidate, phenylbutazone, ranitidine, salicylates, or sulfonamide may increase serum concentrations of hydantoin anticonvulsants because of decreased metabolism, thereby increasing the /hydantoins'/ effects and/or toxicity. Dosage adjustments of the anticonvulsant may be necessary. In addition, the anticoagulant effect of coumarin- or indandione-derivative anticoagulants may be increased initially, but decrease with continued concurrent use. /Hydantoin anticonvulsants/For more Interactions (Complete) data for FOSPHENYTOIN (23 total), please visit the HSDB record page. |
Anwendungen & Verwendung
Beschreibung
Cerebyx was launched for the treatment of status epilepticus and for neurosurgery derived seizures. Fosphenytoin is rapidly converted by phosphatases to phenytoin. This compound is readily water soluble thus overcoming an important problem associated with Dilantin.
Verwenden
Anticonvulsant.